Patent: 10,064,938
✉ Email this page to a colleague
Summary for Patent: 10,064,938
Title: | Localized immunosuppression of allografts for peripheral nerve repair |
Abstract: | Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient\'s entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein. |
Inventor(s): | Bushman; Jared (Laramie, WY) |
Assignee: | UNIVERSITY OF WYOMING (Laramie, WY) |
Application Number: | 15/457,359 |
Patent Claims: | see list of patent claims |
Details for Patent 10,064,938
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Pharmacia & Upjohn Company Llc | ATGAM | lymphocyte immune globulin, anti-thymocyte globulin (equine) | Injection | 103676 | 12/04/1996 | ⤷ Try a Trial | 2036-03-11 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2036-03-11 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2036-03-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |